 CYPHER® Stent Clinical Trials Results
|
|
CYPHER® Stent is one of the most studied medical devices in history.
Its effectiveness has been proven in more than 75 clinical studies. More than 45,000 people with the CYPHER® Stent have been studied over the past ten years. And over 850 articles have been published about sirolimus, the unique medication released by CYPHER® Stent. Recent meta-analyses of previous studies further support the CYPHER® Stent's consistent level of safety and performance. |
|
|
|
The ground-breaking design of the CYPHER® Stent gives physicians an option for their patients that offers unsurpassed efficacy, remarkable safety and exceptional clinical results.
Benefits of the the CYPHER® Stent include:
- The release kinetics of sirolimus provides anti-proliferative and anti-inflammatory effects, reducing the need for TLR by more than 70%.
- Its closed-cell design provides consistent scaffolding with minimal recoil for more uniform vessel coverage and drug distribution.
- The CYPHER® Stent has consistently proven to control late loss across all vessel sizes and across a broad patient population. In fact, the CYPHER® Stent has shown more than 70% risk reduction in target lesion revascularization (TLR) when compared with bare metal stents. Clinical trials have supported this statistic with a confidence value of P<.0001.
- The CYPHER® Stent is the most studied drug-eluting stent in the world, and has a proven safety profile out to 5 years.
While offering significant clinical advantages to a bare metal stent, the CYPHER® Stent has shown a comparable safety profile to bare metal stents for thrombosis, myocardial infarction, and death. |
|
Additional information on the design, safety, efficacy, and use of the CYPHER® Stent is available from the Cordis Medical Information Center at 1-800-781-0282. | |
|
|
|
|